ConductScience.org, home

Paper6146751

Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.

Johnston DG and 5 others. Lancet, 1984. Cited by 91 papers, by iCite.

Cite this record

ConductScience Library. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Papers, record 6146751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6146751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.
PubMed
Journal
Lancet
PubMed
Year
1984
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
91
iCite
Relative citation ratio, by iCite
4.5
iCite
Revised in PubMed
2019-06-11
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Johnston DGD G
2Hall KK
3Kendall-Taylor PP
4Patrick DD
5Watson MM
6Cook DBD B

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BromocriptineMajor topic
DopamineMajor topic
ErgolinesMajor topic
Pituitary NeoplasmsMajor topic
ProlactinMajor topic
Adult
Aged
Female
Humans
Male
Middle Aged
Pergolide
Pituitary Function Tests
Pregnancy
Sella Turcica
Tomography, X-Ray Computed

Source PubMed

Download CSV of topics

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.

PMIDTitleJournalYearIn PapersSource
36974474Approach to the Patient With Prolactinoma.J Clin Endocrinol Metab2023https://conductscience.org/library/papers/36974474PubMed
34774043The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis.BMC Endocr Disord2021https://conductscience.org/library/papers/34774043PubMed
31556013Dopamine agonists in prolactinomas: when to withdraw?Pituitary2020https://conductscience.org/library/papers/31556013PubMed
29404245Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.J Neurol Surg B Skull Base2018https://conductscience.org/library/papers/29404245PubMed
26830552Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?Pituitary2016https://conductscience.org/library/papers/26830552PubMed
21423245Medical treatment of prolactinomas.Nat Rev Endocrinol2011https://conductscience.org/library/papers/21423245PubMed
21409614Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience.Pituitary2012https://conductscience.org/library/papers/21409614PubMed
17917811Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.Pituitary2008https://conductscience.org/library/papers/17917811PubMed
12675502Medical management of prolactin-secreting pituitary adenomas.Pituitary2002https://conductscience.org/library/papers/12675502PubMed
12668871Hyperprolactinemia in men: clinical and biochemical features and response to treatment.Endocrine2003https://conductscience.org/library/papers/12668871PubMed
11383485Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.Pituitary2000https://conductscience.org/library/papers/11383485PubMed
9413808Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.J Endocrinol Invest1997https://conductscience.org/library/papers/9413808PubMed
3917709Long term suppression of prolactin concentrations after bromocriptine induced regression of pituitary prolactinomas.Br Med J (Clin Res Ed)1985https://conductscience.org/library/papers/3917709PubMed
2863782Present status of neurosurgery in the treatment of prolactinomas.Neurosurg Rev1985https://conductscience.org/library/papers/2863782PubMed
2863300Medical treatment of pituitary adenomas: effects on tumor growth.J Endocrinol Invest1985https://conductscience.org/library/papers/2863300PubMed
2184010Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.Drugs1990https://conductscience.org/library/papers/2184010PubMed
2035258Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.Virchows Arch A Pathol Anat Histopathol1991https://conductscience.org/library/papers/2035258PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PRL5617PubTator's text mininghttps://conductscience.org/library/genes/5617

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6146751

GET https://conductscience.org/api/papers/v1/6146751/authors